Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) revealed positive interim data from the second-stage study of KRN23 for
tumor-induced osteomalacia (TIO) treatment. The company indicated its interim data at 24 weeks from the first eight patients showed
KRN23 improved serum phosphorus levels and bone metabolism measures. This included a patient with epidermal nevus syndrome or
ENS.
The company is conducting the second-stage study through a collaboration and license agreement with Kyowa Hakko Kirin. The
company said these data were presented at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting on
Monday.
Related Link: Biotech's
"New Sweetheart": Janney Upgrades Sarepta To Buy
Ultragenyx CEO and President Emil Kakkis said, "Patients with TIO have substantial hypophosphatemia, osteomalacia and fractures.
These data support that KRN23 could potentially reverse some of these symptoms and improve bone health in patients."
The company disclosed that overall the study demonstrated improvement in serum phosphorus and other bone mineral metabolism
measures that is in line with what was observed in trials of KRN23 in pediatric and adult patients with X-linked hypophosphatemia
(XLH).
Following the news, the stock advanced $1.38, or 1.79 percent, to $78.50 in the pre-market trading on Monday. At time of
publication, the stock was up 3.12 percent at $79.53.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.